SK284723B6 - Použitie inhibítora farnesyl-proteín transferázy na prípravu farmaceutickej kompozície, majúcej rádiosenzibilizačné vlastnosti - Google Patents

Použitie inhibítora farnesyl-proteín transferázy na prípravu farmaceutickej kompozície, majúcej rádiosenzibilizačné vlastnosti Download PDF

Info

Publication number: SK284723B6
Authority: SK; Slovakia
Prior art keywords: alkyl; methyl; hydrogen; formula; alkoxy
Prior art date: 1998-07-06

Application number

SK1986-2000A

Other languages

English (en)

Slovak (sk)

Other versions

SK19862000A3 (sk

Inventor

Ginckel Robert Franciscus Van

Wim Joanna Floren

David William End

Walter Boudewijn Leopold Wouters

Original Assignee

Janssen Pharmaceutica N. V.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-07-06

Filing date

1999-06-30

Publication date

2005-10-06

1999-06-30 Application filed by Janssen Pharmaceutica N. V. filed Critical Janssen Pharmaceutica N. V.

2001-12-03 Publication of SK19862000A3 publication Critical patent/SK19862000A3/sk

2005-10-06 Publication of SK284723B6 publication Critical patent/SK284723B6/sk

Links

239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 19
230000000637 radiosensitizating effect Effects 0.000 title claims abstract description 9
238000002360 preparation method Methods 0.000 title claims abstract description 8
239000003528 protein farnesyltransferase inhibitor Substances 0.000 title abstract 3
150000001875 compounds Chemical class 0.000 claims abstract description 68
206010028980 Neoplasm Diseases 0.000 claims abstract description 36
238000001727 in vivo Methods 0.000 claims abstract description 12
229910052760 oxygen Inorganic materials 0.000 claims abstract description 6
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 5
239000001301 oxygen Substances 0.000 claims abstract description 5
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims abstract description 3
125000000217 alkyl group Chemical group 0.000 claims description 133
229910052739 hydrogen Inorganic materials 0.000 claims description 53
239000001257 hydrogen Substances 0.000 claims description 52
150000002431 hydrogen Chemical class 0.000 claims description 35
125000003545 alkoxy group Chemical group 0.000 claims description 32
-1 4,4-dimethyloxazolyl Chemical group 0.000 claims description 26
229910052736 halogen Inorganic materials 0.000 claims description 20
150000002367 halogens Chemical class 0.000 claims description 20
150000003839 salts Chemical class 0.000 claims description 17
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 16
239000002253 acid Substances 0.000 claims description 16
230000005855 radiation Effects 0.000 claims description 16
125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 15
239000003558 transferase inhibitor Substances 0.000 claims description 15
125000004356 hydroxy functional group Chemical group O* 0.000 claims description 12
229940123468 Transferase inhibitor Drugs 0.000 claims description 11
125000004448 alkyl carbonyl group Chemical group 0.000 claims description 10
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 10
125000004093 cyano group Chemical group *C#N 0.000 claims description 9
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 9
238000011282 treatment Methods 0.000 claims description 8
125000003282 alkyl amino group Chemical group 0.000 claims description 7
150000001413 amino acids Chemical class 0.000 claims description 7
125000002883 imidazolyl group Chemical group 0.000 claims description 7
102000004169 proteins and genes Human genes 0.000 claims description 6
108090000623 proteins and genes Proteins 0.000 claims description 6
102000004357 Transferases Human genes 0.000 claims description 5
108090000992 Transferases Proteins 0.000 claims description 5
239000003112 inhibitor Substances 0.000 claims description 5
125000004951 trihalomethoxy group Chemical group 0.000 claims description 5
238000000034 method Methods 0.000 claims description 4
125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 claims description 3
125000003342 alkenyl group Chemical group 0.000 claims description 3
229910052799 carbon Inorganic materials 0.000 claims description 3
230000005865 ionizing radiation Effects 0.000 claims description 3
125000004953 trihalomethyl group Chemical group 0.000 claims description 3
WOYOASASOHZEDR-UHFFFAOYSA-N 4-(3-chlorophenyl)-6-[(4-chlorophenyl)-hydroxy-(3-methylimidazol-4-yl)methyl]-1-methylquinolin-2-one Chemical group CN1C=NC=C1C(O)(C=1C=C2C(C=3C=C(Cl)C=CC=3)=CC(=O)N(C)C2=CC=1)C1=CC=C(Cl)C=C1 WOYOASASOHZEDR-UHFFFAOYSA-N 0.000 claims description 2
ZMLMGCPNMBRTKN-UHFFFAOYSA-N 6-[(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-ethoxyphenyl)-1-methylquinolin-2-one;hydrate;hydrochloride Chemical compound O.Cl.CCOC1=CC=CC(C=2C3=CC(=CC=C3N(C)C(=O)C=2)C(C=2N(C=NC=2)C)C=2C=CC(Cl)=CC=2)=C1 ZMLMGCPNMBRTKN-UHFFFAOYSA-N 0.000 claims description 2
QOFQBGVDXIFFKM-UHFFFAOYSA-N 6-[(4-chlorophenyl)-hydroxy-(3-methylimidazol-4-yl)methyl]-4-(3-ethoxyphenyl)-1-methylquinolin-2-one Chemical compound CCOC1=CC=CC(C=2C3=CC(=CC=C3N(C)C(=O)C=2)C(O)(C=2N(C=NC=2)C)C=2C=CC(Cl)=CC=2)=C1 QOFQBGVDXIFFKM-UHFFFAOYSA-N 0.000 claims description 2
WGMCQDUEXBLNFK-UHFFFAOYSA-N 6-[amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-1-methyl-4-(3-propylphenyl)quinolin-2-one Chemical compound CCCC1=CC=CC(C=2C3=CC(=CC=C3N(C)C(=O)C=2)C(N)(C=2N(C=NC=2)C)C=2C=CC(Cl)=CC=2)=C1 WGMCQDUEXBLNFK-UHFFFAOYSA-N 0.000 claims description 2
125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 2
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 2
229910052731 fluorine Inorganic materials 0.000 claims description 2
ORTFAQDWJHRMNX-UHFFFAOYSA-N hydroxidooxidocarbon(.) Chemical group O[C]=O ORTFAQDWJHRMNX-UHFFFAOYSA-N 0.000 claims description 2
125000002768 hydroxyalkyl group Chemical group 0.000 claims description 2
229910052717 sulfur Chemical group 0.000 claims description 2
239000011593 sulfur Chemical group 0.000 claims description 2
125000004030 farnesyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
PLHJCIYEEKOWNM-UHFFFAOYSA-N 6-[amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one Chemical compound CN1C=NC=C1C(N)(C=1C=C2C(C=3C=C(Cl)C=CC=3)=CC(=O)N(C)C2=CC=1)C1=CC=C(Cl)C=C1 PLHJCIYEEKOWNM-UHFFFAOYSA-N 0.000 claims 1
ALKQAQOKGRWMSJ-UHFFFAOYSA-N 6-[amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-ethoxyphenyl)-1-methylquinolin-2-one Chemical compound CCOC1=CC=CC(C=2C3=CC(=CC=C3N(C)C(=O)C=2)C(N)(C=2N(C=NC=2)C)C=2C=CC(Cl)=CC=2)=C1 ALKQAQOKGRWMSJ-UHFFFAOYSA-N 0.000 claims 1
125000004457 alkyl amino carbonyl group Chemical group 0.000 claims 1
125000003806 alkyl carbonyl amino group Chemical group 0.000 claims 1
125000004414 alkyl thio group Chemical group 0.000 claims 1
125000001475 halogen functional group Chemical group 0.000 claims 1
PLHJCIYEEKOWNM-HHHXNRCGSA-N tipifarnib Chemical compound CN1C=NC=C1[C@](N)(C=1C=C2C(C=3C=C(Cl)C=CC=3)=CC(=O)N(C)C2=CC=1)C1=CC=C(Cl)C=C1 PLHJCIYEEKOWNM-HHHXNRCGSA-N 0.000 claims 1
239000005864 Sulphur Chemical group 0.000 abstract 1
125000001309 chloro group Chemical group Cl* 0.000 description 40
150000003254 radicals Chemical class 0.000 description 16
239000002585 base Substances 0.000 description 11
239000000203 mixture Substances 0.000 description 11
125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 10
238000012360 testing method Methods 0.000 description 8
241001465754 Metazoa Species 0.000 description 7
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 7
239000000243 solution Substances 0.000 description 7
235000001014 amino acid Nutrition 0.000 description 6
229940024606 amino acid Drugs 0.000 description 6
210000004027 cell Anatomy 0.000 description 6
125000004169 (C1-C6) alkyl group Chemical group 0.000 description 5
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
125000004432 carbon atom Chemical group C* 0.000 description 5
230000000694 effects Effects 0.000 description 5
IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 5
239000002674 ointment Substances 0.000 description 5
239000002904 solvent Substances 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
239000000460 chlorine Substances 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
125000000524 functional group Chemical group 0.000 description 4
229910052757 nitrogen Inorganic materials 0.000 description 4
239000003921 oil Substances 0.000 description 4
235000019198 oils Nutrition 0.000 description 4
235000018102 proteins Nutrition 0.000 description 4
239000003826 tablet Substances 0.000 description 4
201000003793 Myelodysplastic syndrome Diseases 0.000 description 3
206010061902 Pancreatic neoplasm Diseases 0.000 description 3
239000002775 capsule Substances 0.000 description 3
208000029742 colonic neoplasm Diseases 0.000 description 3
239000003937 drug carrier Substances 0.000 description 3
239000000499 gel Substances 0.000 description 3
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
239000004615 ingredient Substances 0.000 description 3
230000002401 inhibitory effect Effects 0.000 description 3
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 3
201000002528 pancreatic cancer Diseases 0.000 description 3
239000007787 solid Substances 0.000 description 3
239000000725 suspension Substances 0.000 description 3
230000004614 tumor growth Effects 0.000 description 3
239000004475 Arginine Substances 0.000 description 2
239000004215 Carbon black (E152) Substances 0.000 description 2
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
206010018338 Glioma Diseases 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
239000004472 Lysine Substances 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
239000000654 additive Substances 0.000 description 2
230000033115 angiogenesis Effects 0.000 description 2
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
201000011510 cancer Diseases 0.000 description 2
239000000969 carrier Substances 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
229910052801 chlorine Inorganic materials 0.000 description 2
239000006071 cream Substances 0.000 description 2
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
239000008103 glucose Substances 0.000 description 2
150000004677 hydrates Chemical class 0.000 description 2
229930195733 hydrocarbon Natural products 0.000 description 2
208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 2
208000008443 pancreatic carcinoma Diseases 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
239000006187 pill Substances 0.000 description 2
239000000843 powder Substances 0.000 description 2
239000003380 propellant Substances 0.000 description 2
229930195734 saturated hydrocarbon Natural products 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
230000004083 survival effect Effects 0.000 description 2
239000000375 suspending agent Substances 0.000 description 2
230000009466 transformation Effects 0.000 description 2
230000001131 transforming effect Effects 0.000 description 2
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 1
125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 description 1
125000004890 (C1-C6) alkylamino group Chemical group 0.000 description 1
125000006700 (C1-C6) alkylthio group Chemical group 0.000 description 1
125000006619 (C1-C6) dialkylamino group Chemical group 0.000 description 1
DEVSOMFAQLZNKR-RJRFIUFISA-N (z)-3-[3-[3,5-bis(trifluoromethyl)phenyl]-1,2,4-triazol-1-yl]-n'-pyrazin-2-ylprop-2-enehydrazide Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(C2=NN(\C=C/C(=O)NNC=3N=CC=NC=3)C=N2)=C1 DEVSOMFAQLZNKR-RJRFIUFISA-N 0.000 description 1
CUJPFPXNDSIBPG-UHFFFAOYSA-N 1,3-propanediyl Chemical group [CH2]C[CH2] CUJPFPXNDSIBPG-UHFFFAOYSA-N 0.000 description 1
OMIVCRYZSXDGAB-UHFFFAOYSA-N 1,4-butanediyl Chemical group [CH2]CC[CH2] OMIVCRYZSXDGAB-UHFFFAOYSA-N 0.000 description 1
LFOIDLOIBZFWDO-UHFFFAOYSA-N 2-methoxy-6-[6-methoxy-4-[(3-phenylmethoxyphenyl)methoxy]-1-benzofuran-2-yl]imidazo[2,1-b][1,3,4]thiadiazole Chemical compound N1=C2SC(OC)=NN2C=C1C(OC1=CC(OC)=C2)=CC1=C2OCC(C=1)=CC=CC=1OCC1=CC=CC=C1 LFOIDLOIBZFWDO-UHFFFAOYSA-N 0.000 description 1
125000006024 2-pentenyl group Chemical group 0.000 description 1
125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
240000005369 Alstonia scholaris Species 0.000 description 1
239000005995 Aluminium silicate Substances 0.000 description 1
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
208000003950 B-cell lymphoma Diseases 0.000 description 1
206010005003 Bladder cancer Diseases 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
208000026310 Breast neoplasm Diseases 0.000 description 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
208000011691 Burkitt lymphomas Diseases 0.000 description 1
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
125000003830 C1- C4 alkylcarbonylamino group Chemical group 0.000 description 1
206010048832 Colon adenoma Diseases 0.000 description 1
208000001333 Colorectal Neoplasms Diseases 0.000 description 1
SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
208000032612 Glial tumor Diseases 0.000 description 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
206010021143 Hypoxia Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
206010023347 Keratoacanthoma Diseases 0.000 description 1
208000008839 Kidney Neoplasms Diseases 0.000 description 1
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
238000000585 Mann–Whitney U test Methods 0.000 description 1
239000004909 Moisturizer Substances 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
206010029260 Neuroblastoma Diseases 0.000 description 1
206010033128 Ovarian cancer Diseases 0.000 description 1
206010061535 Ovarian neoplasm Diseases 0.000 description 1
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
206010038389 Renal cancer Diseases 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
239000004473 Threonine Substances 0.000 description 1
208000033781 Thyroid carcinoma Diseases 0.000 description 1
208000024770 Thyroid neoplasm Diseases 0.000 description 1
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
208000009956 adenocarcinoma Diseases 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
150000001340 alkali metals Chemical class 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
235000012211 aluminium silicate Nutrition 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
150000003863 ammonium salts Chemical class 0.000 description 1
229940027991 antiseptic and disinfectant quinoline derivative Drugs 0.000 description 1
235000009582 asparagine Nutrition 0.000 description 1
229960001230 asparagine Drugs 0.000 description 1
235000003704 aspartic acid Nutrition 0.000 description 1
238000011717 athymic nude mouse Methods 0.000 description 1
125000004429 atom Chemical group 0.000 description 1
206010004398 benign neoplasm of skin Diseases 0.000 description 1
JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000037396 body weight Effects 0.000 description 1
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
229910052794 bromium Inorganic materials 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
159000000007 calcium salts Chemical class 0.000 description 1
125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
229910002092 carbon dioxide Inorganic materials 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
201000010897 colon adenocarcinoma Diseases 0.000 description 1
235000005687 corn oil Nutrition 0.000 description 1
239000002285 corn oil Substances 0.000 description 1
235000012343 cottonseed oil Nutrition 0.000 description 1
239000002385 cottonseed oil Substances 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
239000006196 drop Substances 0.000 description 1
239000003814 drug Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
239000003889 eye drop Substances 0.000 description 1
229940012356 eye drops Drugs 0.000 description 1
239000003925 fat Substances 0.000 description 1
239000011737 fluorine Substances 0.000 description 1
238000009472 formulation Methods 0.000 description 1
238000005194 fractionation Methods 0.000 description 1
239000007789 gas Substances 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
150000002314 glycerols Chemical class 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
210000004013 groin Anatomy 0.000 description 1
244000144993 groups of animals Species 0.000 description 1
230000012010 growth Effects 0.000 description 1
230000003394 haemopoietic effect Effects 0.000 description 1
125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical class C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
230000001146 hypoxic effect Effects 0.000 description 1
125000000336 imidazol-5-yl group Chemical group [H]N1C([H])=NC([H])=C1[*] 0.000 description 1
239000007972 injectable composition Substances 0.000 description 1
239000000543 intermediate Substances 0.000 description 1
239000011630 iodine Substances 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
229960000310 isoleucine Drugs 0.000 description 1
NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
201000010982 kidney cancer Diseases 0.000 description 1
239000007788 liquid Substances 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
150000004668 long chain fatty acids Chemical class 0.000 description 1
239000006210 lotion Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
208000037841 lung tumor Diseases 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
201000001441 melanoma Diseases 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
230000001333 moisturizer Effects 0.000 description 1
208000025113 myeloid leukemia Diseases 0.000 description 1
125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000007922 nasal spray Substances 0.000 description 1
125000004433 nitrogen atom Chemical group N* 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
238000011275 oncology therapy Methods 0.000 description 1
239000008203 oral pharmaceutical composition Substances 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
239000012057 packaged powder Substances 0.000 description 1
125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
239000003961 penetration enhancing agent Substances 0.000 description 1
125000002958 pentadecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 1
125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
238000001959 radiotherapy Methods 0.000 description 1
230000004044 response Effects 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
239000002453 shampoo Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
239000008247 solid mixture Substances 0.000 description 1
239000003549 soybean oil Substances 0.000 description 1
235000012424 soybean oil Nutrition 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
150000003457 sulfones Chemical class 0.000 description 1
150000003462 sulfoxides Chemical class 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
208000001608 teratocarcinoma Diseases 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
201000002510 thyroid cancer Diseases 0.000 description 1
208000013077 thyroid gland carcinoma Diseases 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
239000012049 topical pharmaceutical composition Substances 0.000 description 1
125000002889 tridecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
230000004565 tumor cell growth Effects 0.000 description 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
125000002948 undecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
201000005112 urinary bladder cancer Diseases 0.000 description 1
239000004474 valine Substances 0.000 description 1
125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
235000012431 wafers Nutrition 0.000 description 1
238000005303 weighing Methods 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Plural Heterocyclic Compounds (AREA)
Enzymes And Modification Thereof (AREA)

SK1986-2000A 1998-07-06 1999-06-30 Použitie inhibítora farnesyl-proteín transferázy na prípravu farmaceutickej kompozície, majúcej rádiosenzibilizačné vlastnosti SK284723B6 (sk)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP98202257		1998-07-06
EP98204330		1998-12-18
PCT/EP1999/004545 WO2000001411A1 (fr)	1998-07-06	1999-06-30	Inhibiteurs de farnesyl proteine transferase a proprietes de radiosensibilisation in vivo

Publications (2)

Publication Number	Publication Date
SK19862000A3 SK19862000A3 (sk)	2001-12-03
SK284723B6 true SK284723B6 (sk)	2005-10-06

Family

ID=26150503

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK1986-2000A SK284723B6 (sk)	1998-07-06	1999-06-30	Použitie inhibítora farnesyl-proteín transferázy na prípravu farmaceutickej kompozície, majúcej rádiosenzibilizačné vlastnosti

Country Status (30)

Country	Link
US (1)	US6545020B1 (fr)
EP (1)	EP1094839B1 (fr)
JP (1)	JP4530537B2 (fr)
KR (1)	KR100591603B1 (fr)
CN (1)	CN1152716C (fr)
AP (1)	AP1599A (fr)
AT (1)	ATE238811T1 (fr)
AU (1)	AU762423B2 (fr)
BG (1)	BG64941B1 (fr)
BR (1)	BR9911861A (fr)
CA (1)	CA2336624C (fr)
CZ (1)	CZ300968B6 (fr)
DE (1)	DE69907461T2 (fr)
DK (1)	DK1094839T3 (fr)
EA (1)	EA003877B1 (fr)
EE (1)	EE04582B1 (fr)
ES (1)	ES2199579T3 (fr)
HR (1)	HRP20000903A2 (fr)
HU (1)	HU229076B1 (fr)
ID (1)	ID26987A (fr)
IL (2)	IL140721A0 (fr)
MY (1)	MY126519A (fr)
NO (1)	NO328178B1 (fr)
PL (1)	PL193464B1 (fr)
PT (1)	PT1094839E (fr)
SI (1)	SI1094839T1 (fr)
SK (1)	SK284723B6 (fr)
TR (1)	TR200003879T2 (fr)
TW (1)	TW586937B (fr)
WO (1)	WO2000001411A1 (fr)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ID26987A (id)	1998-07-06	2001-02-22	Janssen Pharmaceutica Nv	Inhibitor-inhibitor transferase protein farnesil dengan sifat-sifat peka terhadap sinar radiasi in vivo
HRP20000904A2 (en)	1998-07-06	2001-12-31	Janssen Pharmaceutica Nv	Farnesyl protein transferase inhibitors for treating arthropathies
PT1255537E (pt) *	2000-02-04	2006-09-29	Janssen Pharmaceutica Nv	Inibidores da proteina farnesil transferase para tratar cancro da mama
JO2361B1 (en) *	2000-06-22	2006-12-12	جانسين فارماسيوتيكا ان. في	Enaniumer 1,2-anylated quinoline inhibitor for the transporter - farnesyl
WO2002024683A1 (fr)	2000-09-25	2002-03-28	Janssen Pharmaceutica N.V.	Derives de la quinoleine et de la quinazoline 6-[(phenyle substitue)methyle] inhibiteurs de la farnesyle transferase
US7053105B2 (en)	2000-09-25	2006-05-30	Janssen Pharmaceutica, N.V.	Farnesyl transferase inhibiting quinoline and quinazoline derivatives as farnesyl transferase inhibitors
ATE409189T1 (de)	2000-09-25	2008-10-15	Janssen Pharmaceutica Nv	Farnesyl transferase-hemmende 6- heterocyclylmethyl-chinolin und chinazol-derivate
JP4974439B2 (ja)	2000-09-25	2012-07-11	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	ファルネシルトランスフェラーゼを阻害する６−ヘテロシクリルメチルキノリノン誘導体
ES2328225T3 (es)	2000-11-21	2009-11-11	Janssen Pharmaceutica Nv	Derivados benzoheterociclicos inhibidores de la farnesil-transferasa.
ATE319704T1 (de)	2000-12-27	2006-03-15	Janssen Pharmaceutica Nv	Farnesyltransferase hemmende, in der 4-stellung substituierte chinolin- und chinazolinderivate
EP1351954B1 (fr) *	2000-12-27	2006-05-03	Janssen Pharmaceutica N.V.	Derives de 4-heterocyclyl-quinoline et quinazoline inhibant lafarnesyl-transferase
WO2003000266A1 (fr)	2001-06-21	2003-01-03	Ariad Pharmaceuticals, Inc.	Nouvelles quinoleines et leurs utilisations
CA2469275C (fr)	2001-12-19	2011-09-06	Janssen Pharmaceutica N.V.	Utilisation de derives de quinoline 1,8-anneles substitues avec des triazoles lies par le carbone en tant qu'inhibiteurs de farnesyl transferase
ES2287466T3 (es)	2002-03-22	2007-12-16	Janssen Pharmaceutica N.V.	Derivados de 2-quinolinona y quinazolina de bencilimidazolil sustituidas como inhibidores de la farnesil transferasa.
CA2481480C (fr)	2002-04-15	2011-04-12	Janssen Pharmaceutica N.V.	Derives de quinazoline tricylique inhibant la farnesyl transferase substitues avec des imidazoles ou des triazoles a liaison carbone
NZ546991A (en) *	2003-11-20	2010-01-29	Janssen Pharmaceutica Nv	6-Alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as PARP inhibitors
JP4691041B2 (ja)	2003-11-20	2011-06-01	チルドレンズホスピタルメディカルセンター	Ｇｔｐアーゼ阻害剤および使用方法
US20070293539A1 (en) *	2004-03-18	2007-12-20	Lansbury Peter T	Methods for the treatment of synucleinopathies
WO2005089515A2 (fr) *	2004-03-18	2005-09-29	The Brigham And Women's Hospital, Inc.	Procedes de traitement des synucleinopathies
CA2559221A1 (fr) *	2004-03-18	2005-09-29	Brigham And Women's Hospital, Inc.	Procedes pour le traitement de synucleinopathies
US20050288298A1 (en) *	2004-03-18	2005-12-29	The Brigham And Women's Hospital, Inc.	Methods for the treatment of synucleinopathies
CA2559285A1 (fr) *	2004-03-18	2005-09-29	Brigham And Women's Hospital, Inc.	Traitement des synucleinopathies
US20050272068A1 (en) *	2004-03-18	2005-12-08	The Brigham And Women's Hospital, Inc.	UCH-L1 expression and cancer therapy
US20060194821A1 (en) *	2005-02-18	2006-08-31	The Brigham And Women's Hospital, Inc.	Compounds inhibiting the aggregation of superoxide dismutase-1
WO2007016539A2 (fr)	2005-07-29	2007-02-08	Children's Hospital Medical Center	Inhibiteurs de gtpase et methodes d'utilisation et structure cristalline de la gtpase rac-1
AU2006331542A1 (en)	2005-12-23	2007-07-05	Link Medicine Corporation	Treatment of synucleinopathies
US8124774B2 (en) *	2007-05-23	2012-02-28	Allergan, Inc.	Therapeutic ((phenyl)imidazolyl)methylquinolinyl compounds
WO2009151683A2 (fr) *	2008-03-12	2009-12-17	Link Medicine Corporation	Inhibiteurs de quinolinone farnésyl transférase pour le traitement de synucléinopathies et d'autres indications
ATE555384T1 (de)	2008-06-26	2012-05-15	Spherotec Gmbh	Verfahren zum testen der reaktion von zellen auf die einwirkung von therapeutika
US20110060005A1 (en) *	2008-11-13	2011-03-10	Link Medicine Corporation	Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
US20100331363A1 (en) *	2008-11-13	2010-12-30	Link Medicine Corporation	Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
AU2009313927A1 (en) *	2008-11-13	2010-05-20	Astrazeneca Ab	Azaquinolinone derivatives and uses thereof
US9980942B2 (en)	2012-05-02	2018-05-29	Children's Hospital Medical Center	Rejuvenation of precursor cells
HK1213887A1 (zh)	2012-10-16	2016-07-15	Janssen Pharmaceutica N.V.	RORγt的苯基连接的喹啉基调节剂
MY189505A (en)	2012-10-16	2022-02-16	Janssen Pharmaceutica Nv	Methylene linked quinolinyl modulators of roryt
WO2014062655A1 (fr)	2012-10-16	2014-04-24	Janssen Pharmaceutica Nv	Modulateurs de roryt de type quinolinyle à liaison hétéroaryle
US9284308B2 (en)	2013-10-15	2016-03-15	Janssen Pharmaceutica Nv	Methylene linked quinolinyl modulators of RORγt
US9403816B2 (en)	2013-10-15	2016-08-02	Janssen Pharmaceutica Nv	Phenyl linked quinolinyl modulators of RORγt
CA2927182A1 (fr)	2013-10-15	2015-04-23	Janssen Pharmaceutica Nv	Modulateurs quinolinyl de ror.gamma.t
CA2926339A1 (fr)	2013-10-15	2015-04-23	Janssen Pharmaceutica Nv	Modulateurs quinolinyl a liaison alkyle de roryt
US9221804B2 (en)	2013-10-15	2015-12-29	Janssen Pharmaceutica Nv	Secondary alcohol quinolinyl modulators of RORγt
US10555941B2 (en)	2013-10-15	2020-02-11	Janssen Pharmaceutica Nv	Alkyl linked quinolinyl modulators of RORγt
US9328095B2 (en)	2013-10-15	2016-05-03	Janssen Pharmaceutica Nv	Heteroaryl linked quinolinyl modulators of RORgammat
US10028503B2 (en)	2014-06-18	2018-07-24	Children's Hospital Medical Center	Platelet storage methods and compositions for same
US10471055B2 (en)	2015-08-17	2019-11-12	Kura Oncology, Inc.	Methods of treating cancer patients with farnesyltransferase inhibitors
US20190119758A1 (en)	2016-04-22	2019-04-25	Kura Oncology, Inc.	Methods of selecting cancer patients for treatment with farnesyltransferase inhibitors
HRP20210544T1 (hr)	2016-11-03	2021-08-20	Kura Oncology, Inc.	Inhibitori farneziltransferaze za uporabu u liječenju raka
WO2018156609A1 (fr)	2017-02-21	2018-08-30	Kura Oncology, Inc.	Méthodes de traitement du cancer avec des inhibiteurs de la farnésyltransférase
US10137121B2 (en)	2017-02-21	2018-11-27	Kura Oncology, Inc.	Methods of treating cancer with farnesyltransferase inhibitors
US10806730B2 (en)	2017-08-07	2020-10-20	Kura Oncology, Inc.	Methods of treating cancer with farnesyltransferase inhibitors
CA3071854A1 (fr)	2017-08-07	2019-02-14	Kura Oncology, Inc.	Methodes de traitement du cancer avec des inhibiteurs de la farnesyltransferase
WO2019113269A1 (fr)	2017-12-08	2019-06-13	Kura Oncology, Inc.	Méthodes de traitement de patients cancéreux avec des inhibiteurs de la farnésyltransférase
AU2019372141A1 (en)	2018-11-01	2021-05-27	Kura Oncology, Inc.	Methods of treating cancer with farnesyltransferase inhibitors
WO2020180663A1 (fr)	2019-03-01	2020-09-10	Kura Oncology, Inc.	Méthodes de traitement du cancer à l'aide d'inhibiteurs de farnésyltransférase
US20220143006A1 (en)	2019-03-15	2022-05-12	Kura Oncology, Inc.	Methods of treating cancer with farnesyltransferase inhibitors
WO2020205486A1 (fr)	2019-03-29	2020-10-08	Kura Oncology, Inc.	Procédés de traitement de carcinomes squameux par des inhibiteurs de farnésyltransférase
TW202102218A (zh)	2019-04-01	2021-01-16	美商庫拉腫瘤技術股份有限公司	以法呢基(farnesyl)轉移酶抑制劑治療癌症的方法
US20220305001A1 (en)	2019-05-02	2022-09-29	Kura Oncology, Inc.	Methods of treating acute myeloid leukemia with farnesyltransferase inhibitors
CN114450027A (zh)	2019-08-16	2022-05-06	儿童医院医疗中心	用cdc42特异性抑制剂治疗受试者的方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5141851A (en) *	1990-04-18	1992-08-25	Board Of Regents, The University Of Texas System	Isolated farnesyl protein transferase enzyme
US6083917A (en) *	1990-04-18	2000-07-04	Board Of Regents, The University Of Texas System	Methods and compositions for the identification, characterization and inhibition of farnesyltransferase
US5602184A (en) *	1993-03-03	1997-02-11	The United States Of America As Represented By Department Of Health And Human Services	Monoterpenes, sesquiterpenes and diterpenes as cancer therapy
TW349948B (en) *	1995-10-31	1999-01-11	Janssen Pharmaceutica Nv	Farnesyl transferase inhibiting 2-quinolone derivatives
DE69635966T2 (de)	1995-12-08	2006-11-30	Janssen Pharmaceutica N.V.	(Imidazol-5-yl)Methyl-2-Chinolinonderivate als Farnesyl Protein transferase Inhibitoren
EP0910385A4 (fr) *	1996-04-15	1999-12-22	Univ Pennsylvania	Sensibilisation de cellules a la radiotherapie et a la chimiotherapie
CA2260216A1 (fr) *	1996-07-15	1998-01-22	Bristol-Myers Squibb Company	Thiadioxobenzodiazepines utilises comme inhibiteurs de la farnesyle proteine transferase
TW591030B (en)	1997-03-10	2004-06-11	Janssen Pharmaceutica Nv	Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles
ID26987A (id)	1998-07-06	2001-02-22	Janssen Pharmaceutica Nv	Inhibitor-inhibitor transferase protein farnesil dengan sifat-sifat peka terhadap sinar radiasi in vivo
TR200201296T2 (tr) *	1999-02-11	2002-07-22	Pfizer Products Inc.	Antikanser maddeleri olarak faydalı heteroaril-ikame edilmiş kinolin-2-on türevleri

1999
- 1999-06-30 ID IDW20010020A patent/ID26987A/id unknown
- 1999-06-30 AT AT99931229T patent/ATE238811T1/de active
- 1999-06-30 PT PT99931229T patent/PT1094839E/pt unknown
- 1999-06-30 BR BR9911861-0A patent/BR9911861A/pt not_active Application Discontinuation
- 1999-06-30 TR TR2000/03879T patent/TR200003879T2/xx unknown
- 1999-06-30 EP EP99931229A patent/EP1094839B1/fr not_active Expired - Lifetime
- 1999-06-30 PL PL99347979A patent/PL193464B1/pl unknown
- 1999-06-30 SI SI9930332T patent/SI1094839T1/xx unknown
- 1999-06-30 SK SK1986-2000A patent/SK284723B6/sk not_active IP Right Cessation
- 1999-06-30 EA EA200100111A patent/EA003877B1/ru not_active IP Right Cessation
- 1999-06-30 CN CNB998082678A patent/CN1152716C/zh not_active Expired - Lifetime
- 1999-06-30 WO PCT/EP1999/004545 patent/WO2000001411A1/fr not_active Ceased
- 1999-06-30 DK DK99931229T patent/DK1094839T3/da active
- 1999-06-30 CA CA002336624A patent/CA2336624C/fr not_active Expired - Lifetime
- 1999-06-30 EE EEP200000794A patent/EE04582B1/xx unknown
- 1999-06-30 CZ CZ20004777A patent/CZ300968B6/cs not_active IP Right Cessation
- 1999-06-30 DE DE69907461T patent/DE69907461T2/de not_active Expired - Lifetime
- 1999-06-30 HU HU0103689A patent/HU229076B1/hu unknown
- 1999-06-30 ES ES99931229T patent/ES2199579T3/es not_active Expired - Lifetime
- 1999-06-30 JP JP2000557857A patent/JP4530537B2/ja not_active Expired - Lifetime
- 1999-06-30 AU AU47805/99A patent/AU762423B2/en not_active Expired
- 1999-06-30 US US09/743,130 patent/US6545020B1/en not_active Expired - Lifetime
- 1999-06-30 HR HR20000903A patent/HRP20000903A2/hr not_active Application Discontinuation
- 1999-06-30 AP APAP/P/2001/002057A patent/AP1599A/en active
- 1999-06-30 IL IL14072199A patent/IL140721A0/xx active IP Right Grant
- 1999-06-30 KR KR1020007014066A patent/KR100591603B1/ko not_active Expired - Lifetime
- 1999-07-01 MY MYPI99002794A patent/MY126519A/en unknown
- 1999-07-05 TW TW088111346A patent/TW586937B/zh not_active IP Right Cessation
2001
- 2001-01-03 BG BG105108A patent/BG64941B1/bg unknown
- 2001-01-04 IL IL140721A patent/IL140721A/en not_active IP Right Cessation
- 2001-01-05 NO NO20010082A patent/NO328178B1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
EE04582B1 (et)	2006-02-15
BG64941B1 (bg)	2006-10-31
CN1152716C (zh)	2004-06-09
IL140721A0 (en)	2002-02-10
PT1094839E (pt)	2003-09-30
NO20010082L (no)	2001-01-05
MY126519A (en)	2006-10-31
CN1311692A (zh)	2001-09-05
ID26987A (id)	2001-02-22
ATE238811T1 (de)	2003-05-15
EE200000794A (et)	2002-06-17
EA003877B1 (ru)	2003-10-30
EP1094839B1 (fr)	2003-05-02
DK1094839T3 (da)	2003-08-18
HK1034451A1 (en)	2001-10-26
HUP0103689A2 (hu)	2002-02-28
JP4530537B2 (ja)	2010-08-25
CZ300968B6 (cs)	2009-09-30
JP2002519389A (ja)	2002-07-02
HRP20000903A2 (en)	2001-12-31
NO20010082D0 (no)	2001-01-05
PL347979A1 (en)	2002-05-06
WO2000001411A1 (fr)	2000-01-13
CZ20004777A3 (en)	2001-05-16
BG105108A (en)	2001-11-30
TR200003879T2 (tr)	2007-01-22
HU229076B1 (en)	2013-07-29
CA2336624C (fr)	2008-10-21
AU4780599A (en)	2000-01-24
CA2336624A1 (fr)	2000-01-13
DE69907461D1 (de)	2003-06-05
KR100591603B1 (ko)	2006-06-20
EA200100111A1 (ru)	2001-06-25
NO328178B1 (no)	2009-12-28
US6545020B1 (en)	2003-04-08
HUP0103689A3 (en)	2003-01-28
BR9911861A (pt)	2001-03-20
DE69907461T2 (de)	2004-02-19
KR20010052770A (ko)	2001-06-25
SI1094839T1 (en)	2003-12-31
TW586937B (en)	2004-05-11
AP1599A (en)	2006-04-27
IL140721A (en)	2008-11-26
ES2199579T3 (es)	2004-02-16
AU762423B2 (en)	2003-06-26
EP1094839A1 (fr)	2001-05-02
PL193464B1 (pl)	2007-02-28
AP2001002057A0 (en)	2001-03-31
SK19862000A3 (sk)	2001-12-03

Legal Events

Date	Code	Title	Description
2019-08-05	MK4A	Expiry of patent	Expiry date: 20190630

Publication	Publication Date	Title
SK19862000A3 (sk)	2001-12-03	Inhibítory farnezyl-proteín transferázy s rádiosenzibilizačnými vlastnosťami in vivo
ES2293972T3 (es)	2008-04-01	Regimen de dosificacion que comprende un inhibidor de la farnesil proteina transferasa para el tratamiento del cancer.
ES2262626T3 (es)	2006-12-01	Inhibidores de farnesil proteina transferasa para tratar cancer de mama.
JP2003525246A (ja)	2003-08-26	白金化合物とのファルネシルタンパク質トランスフェラーゼ阻害剤の組み合わせ剤
SK19872000A3 (sk)	2001-08-06	Inhibítory farnezyl-proteín transferázy na liečbu artropatií
JP2008535902A5 (fr)	2009-04-30
ES2318000T3 (es)	2009-05-01	Combinaciones de inhibidores de la farnesil-protein-transferasa con agentes antiestrogenos.
MX2022014192A (es)	2023-02-14	Metodos para tratar el cancer de prostata.
JP2003525239A (ja)	2003-08-26	タキサン化合物とのファルネシルタンパク質トランスフェラーゼ阻害剤の組み合わせ剤
KR102468480B1 (ko)	2022-11-18	신규한 화합물 및 이를 포함하는 항암 활성 증진용 약학 조성물
JP2023546316A5 (fr)	2024-09-11
JPS59206360A (ja)	1984-11-22	抗ウイルス剤
US8877734B2 (en)	2014-11-04	Seleny-methyluracil compounds, radiosensitizer and pharmaceutical composition using them
ES2317913T3 (es)	2009-05-01	Tratamiento antitumoral combinado que comprende un derivado de la distamicina sustituida por acriloilo y un antimetabolito.
MXPA01000161A (en)	2001-09-07	Farnesyl protein transferase inhibitors with in vivo
US4215146A (en)	1980-07-29	Antiviral amine derivatives of glycerol and propanediols
US4193999A (en)	1980-03-18	Antiviral amine derivatives of propanediols
UA64796C2 (en)	2004-03-15	Farnesyl protein transferase inhibitors with radiosensitizing properties in vivo
TH50842B (th)	2016-08-19	สารยับยั้งฟาร์นีซิลโปรตีนทรานส์เฟอเรสที่มีคุณสมบัติกระตุ้นความไวต่อรังสีในร่างกาย
TH68401A (th)	2005-04-29	สารยับยั้งฟาร์นีซิลโปรตีนทรานส์เฟอเรสที่มีคุณสมบัติกระตุ้นความไวต่อรังสีในร่างกาย
TH1901007379A (th)	2025-02-17	ตัวยับยั้ง kras g12c และวิธีการใช้สิ่งดังกล่าว
RU99128088A (ru)	2001-10-20	Цианоамиды, как ингибиторы пролиферации клеток
TH50842C3 (th)	2016-08-19	สารยับยั้งฟาร์นีซิลโปรตีนทรานส์เฟอเรสที่มีคุณสมบัติกระตุ้นความไวต่อรังสีในร่างกาย